While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

After parting ways with BeiGene in 2023, Novartis effectively bowed ... “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a ...

Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors ... Meanwhile, the U.S. Food and Drug Administration has approved BeiGene (NASDAQ:ONC)'s TEVIMBRA for use in combination ...

a PD-1 checkpoint inhibitor developed by Beigene (NASDAQ:ONC). Jeffrey Meckler, CEO of Indaptus, expressed enthusiasm about the inclusion of Canadian investigators and patients, anticipating a ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Applications (Dialysis; Sterile Processing), Process Technology (Ultrafiltration; Microfiltration), Design/Process, End-Users & Region - Global Forecast ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection ...

Stellaromics, a pioneer in 3D spatial biology spun out of the laboratories of Karl Deisseroth (Stanford University) and Xiao Wang (MIT and Broad Institute), today announced the completion of a Series ...

which pairs Decoy20 with Beigene’s PD-1 checkpoint inhibitor, tislelizumab. Jeffrey Meckler, CEO of Indaptus, commented, “We are pleased to bring Canadian investigators and patients into our ...

This approval aims to enhance patient recruitment and clinical research efforts, with plans to submit an amendment to include a combination trial featuring Decoy20 and Beigene’s PD-1 inhibitor ...